Can a simple pill prevent a common side effect of targeted lung cancer therapy?

NCT ID NCT07418879

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether taking leucogen (a drug that raises white blood cell counts) from the start can prevent low white blood cells in people with RET fusion-positive non-small cell lung cancer who are taking pralsetinib. About 25 people who have not had prior treatment will take both drugs for up to 3 months. The main goal is to see how many develop low white blood cell counts during the first month.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pralsetinib and leucogen
What this could lead to: If it works, this could show that taking leucogen alongside pralsetinib helps prevent a common side effect (low white blood cells), making treatment safer and more tolerable.
What could go wrong: This is a very small, early real-world study with only 25 people and no comparison group. It is not designed to prove pralsetinib works, only to see if leucogen reduces side effects. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma RET fusion positive cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER PRALSETINIB RET FUSION

More trials for these conditions

Other studies related to the condition(s) this trial covers.